ACN Newswire
HONG KONG, Jun 12, 2025 – (ACN Newswire) – At the 62nd Congress of the European Renal Association (ERA 2025), Everest Medicines presented new results findings on both NEFECON® (budesonide delayed release capsules), the world’s first and only approved therapy that directly targets the underlying cause of IgA nephropathy (IgAN…
Read More
NEFECON(R) and EVER001 Drive Synergistic Progress as Everest Medicines Advances
Raleigh Grumbles
18:21
HONG KONG, Jun 12, 2025 – (ACN Newswire) – At the 62nd Congress of the European Renal Association (ERA 2025), Everest Medicines presented new results findings on both NEFECON® (budesonide delayed release capsules), the world’s first and only approved therapy that directly targets the underlying cause of IgA nephropathy (IgAN…
